Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.06.19	Karolinska Development´s Annual General Meeting 2019 (GlobeNewswire)
28.06.19	Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan (GlobeNewswire)
27.06.19	Karolinska Development sells its ownership in Pharmanest for SEK 23 million (GlobeNewswire)
26.06.19	Announcement of the final terms and conditions of Karolinska Development’s directed share issue to the holders of the Company’s convertible loan (GlobeNewswire)
04.06.19	The Swedish Securities Council grants Sino Biopharmaceutical exemption from the mandatory bid obligation (GlobeNewswire)
29.05.19	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
29.05.19	Karolinska Development's Board of Directors proposes measures to resolve the company's convertible loan (GlobeNewswire)
28.05.19	Karolinska Development changes date for the Annual General Meeting (GlobeNewswire)
23.05.19	Karolinska Development’s portfolio company OssDsign reports substantial progress in the process towards reimbursement of OSSDSIGN PSI in France (GlobeNewswire)
21.05.19	Karolinska Development: Q1 2019 Interim Report – January-March (GlobeNewswire)
20.05.19	Karolinska Development’s portfolio company OssDsign’s share issue prior to listing on Nasdaq First North is oversubscribed (GlobeNewswire)
13.05.19	Karolinska Development's portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell disease (GlobeNewswire)
02.05.19	Karolinska Development’s portfolio company OssDsign applies for listing on Nasdaq First North (GlobeNewswire)
30.04.19	Karolinska Development publishes its Annual Report for 2018 with an update on the financial situation (GlobeNewswire)
26.04.19	Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting (GlobeNewswire)
23.04.19	Karolinska Development's portfolio company Dilafor secures financing for continued development of tafoxiparin (GlobeNewswire)
16.04.19	Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-246 (GlobeNewswire)
03.04.19	Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents (GlobeNewswire)
25.03.19	Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer (GlobeNewswire)
15.03.19	Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical (GlobeNewswire)
07.03.19	Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 6219 (GlobeNewswire)
27.02.19	New US investor joins Series C financing of Karolinska Development's portfolio company Aprea Therapeutics (GlobeNewswire)
22.02.19	Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin (GlobeNewswire)
14.02.19	Karolinska Development: Q4 and 2018 Year-End Report - January-December (GlobeNewswire)
12.02.19	Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North (GlobeNewswire)
29.01.19	Karolinska Development's portfolio company Umecrine Cognition presents phase 2a results for GR3027 in idiopathic hypersomnia (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten